Sonnet BioTherapeutics Stock Surges 77.74% Amid Key Updates
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) is a clinical-stage biotechnology company based in Princeton, New Jersey. The company utilizes its proprietary FHAB™ (Fully Human Albumin-Binding) platform to develop targeted immuno-oncology therapeutics. As of July 2, 2025, Sonnet’s share price was USD 2.1507, reflecting a 77.74% increase on heavy volume.
| Ticker | Exchange | Price (USD) | Change (%) | Volume |
|---|---|---|---|---|
| SONN | NASDAQ | 2.1507 | +77.74 | 15,029,953 |
Corporate Structure
Founded in 2011, Sonnet employs between 11 and 50 professionals, with expertise in cytokine biology, clinical development, and regulatory affairs. The leadership team includes Founder and CEO Pankaj Mohan, Ph.D., who oversees the company’s strategic direction, and a board consisting of experienced professionals in biotechnology and pharmaceutical development.
Biotechnology by National Cancer Institute
Key Developments
- December 23, 2024: Sonnet published a new “CEO Corner” segment, in which Pankaj Mohan reviewed 2024 accomplishments and outlined milestones for 2025.
- September 30, 2024: The company implemented a 1-for-8 reverse stock split to meet Nasdaq’s minimum bid price requirement of USD 1.00 per share.
- July 2, 2025: The company filed a Form 8-K related to business operations and corporate governance (Items 1.01, 2.03, 3.02, and 9.01).
- Clinical pipeline updates:
- SON-1010 (IL-12-FHAB) is in a Phase 1 trial, including a combination study with atezolizumab for platinum-resistant ovarian cancer under a Material Supply Agreement with Roche.
- SON-1210 (IL-12-FHAB-IL-15) has entered an investigator-initiated Phase 1/2a study for pancreatic cancer in collaboration with the Sarcoma Oncology Center.
- SON-080 (rhIL-6) completed a Phase 1b/2a trial for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy, with no evidence of a pro-inflammatory cytokine response observed.
Financial and Strategic Analysis
Sonnet is in the research and development investment phase, generating limited to no product revenue. The recent 77.74% share price increase and 15 million-share volume indicate increased investor interest, potentially influenced by advancing clinical data or corporate filings. Key strategic initiatives include:
- Partnering with Roche on combination studies for SON-1010
- Collaborating with academic centers for investigator-initiated trials
- Complying with Nasdaq listing requirements through reverse stock splits
The company’s cash position was strengthened by a private placement financing of USD 19 million concurrent with its merger transaction in 2019. Future funding requirements will depend on clinical progress and strategic partnerships.
Market Position and Industry Context
Sonnet operates in the competitive immuno-oncology sector, where various biotech firms are developing cytokine-based and bispecific biologics. Its FHAB™ platform provides a modular approach, utilizing payloads such as interleukins in combination with human serum albumin to enhance pharmacokinetics and therapeutic efficacy. Sonnet’s pipeline includes indications for solid tumors and neuropathy, positioning it among clinical-stage companies focused on immune modulation.
TL;DR
On July 2, 2025, Sonnet BioTherapeutics’ stock increased by 77.74% to USD 2.1507 on NASDAQ, with a trading volume of 15 million shares. Concurrently, the company filed an 8-K under Items 1.01, 2.03, 3.02, and 9.01. Clinical updates include ongoing Phase 1 trials of SON-1010 in collaboration with Roche and a Phase 1/2a study of SON-1210 for pancreatic cancer. Upcoming milestones will depend on results from these studies and further developments regarding funding or partnerships.